# **Original Article**

# Prevalence of Pulmonary Tuberculosis, Failure of Treatment, and its Related Factors in Kashan During 2004-2017

Fatemeh Atoof<sup>1</sup>, Zeynab Marzhoseyni<sup>2, 3</sup>, Somaye Rashki<sup>2, 3</sup>, Azad Khaledi<sup>2, 3</sup>\*, Mahboobeh Zamani<sup>2, 3</sup>, Mehrdad Hedayati<sup>2, 3</sup>

<sup>1</sup> Department of Biostatistics and Epidemiology, Faculty of Health, Kashan University of Medical Science, Kashan, Iran

<sup>2</sup> Infectious Diseases Research Center, Kashan University of Medical Science, Kashan, Iran

<sup>3</sup> Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Science, Kashan, Iran

Received: 19 September, 2022; Accepted: 28 December, 2022

#### Abstract

**Background:** *Mycobacterium tuberculosis* affects the lungs in 85% of all cases and the remaining 15% through extra pulmonary affecting other parts of the body such as lymph nodes, pleura, and the genitourinary system. This study aimed to investigate extra-pulmonary tuberculosis (TB) associated factors, failure of treatment, and trends between 2004-2017 in Kashan, Iran.

**Materials and Methods:** This study was conducted during 2004-2017 on newly registered extrapulmonary tuberculosis patients referred to TB Referral Center in Isfahan province, Kashan city, Iran. Information (demographic characteristics, related factors of the disease, and treatment status) of 197 extrapulmonary tuberculosis (EPTB) patients was extracted from Medical case records.

**Results:** In total, 527 cases of Tuberculosis were reported, of which, 159 (30.17%) were confirmed extrapulmonary TB. Eighty-five (53.5%) and 74 (46.5%) were male and female, respectively. Also, 74 (46.5%), and 84 (53.5%) of EPTB were from Iran, and Afghanistan immigrants, respectively. The average age of patients was  $41.9\pm2.18$ . Among underlying diseases in extrapulmonary TB positive, diabetes mellitus (DM) was predominant with a prevalence of 31 (19.5%), while, 128 (80.5%) cases did not show any underlying disease. Most of the patients were in the age group (21-40 years) with a frequency of 60 (37.7%), and the lowest of patients belonged to the age group (>80 years) with a frequency of 9 (5.7%). No correlation was found between related factors and infection with EPTB (p> 0.05).

**Conclusion:** Our findings showed that the prevalence of EPTB in Kashan was relatively high, but, a relative decrease was shown during 2004-2017, which with preventative measures can be reduced the prevalence. **Keywords:** Epidemiology, Tuberculosis, Prevalence

\*Corresponding Author: Azad Khaledi (Ph.D.), Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, 5<sup>th</sup> of Qotb-e Ravandi Blvd.P.O. Box: 87155.111, Post Code: 87154, Kashan, Iran. Tel /Fax: + 98 912 7804713/+ 98 361 557 5057. E-Mail:<u>azadkh99@gmail.com</u>

**Please cite this article as:** Atoof F, Marzhoseyni Z, Rashki S, Khaledi A, Hedayati M. Prevalence of Pulmonary Tuberculosis, Failure of Treatment, and its Related Factors in Kashan During 2004-2017. Novel Biomed. 2023;11(1):1-8.

#### Introduction

Nowadays, Tuberculosis (TB) is considered one of the most common infectious diseases worldwide<sup>1</sup>. It can infect all organs of the body, but the lungs are affected

in 85% of cases, and 15% of cases in an extrapulmonary form infected other organs such as lymph nodes, pleura, genitourinary system, bones, joints, and meningitis<sup>2, 3</sup>. The last report from WHO in 2017 showed an estimation of 6.3 million new TB cases globally, of which 16% were Extra-pulmonary TB (EPTB); incidence rates ranged from 8% in the Western Pacific Region to 24% in the Eastern Mediterranean Region<sup>4</sup>. With develop of acquired immunodeficiency syndrome (AIDS) infection, the incidence of EPTB is also increasing and becomes an international problem<sup>5</sup>. EPTB is responsible for 15 to 20 % of all forms in individuals who do not have human immunodeficiency virus (HIV) infection<sup>6, 7</sup>.

EPTB is somewhat neglected and compared to pulmonary tuberculosis (PTB) rising in prevalence in low-burden countries<sup>8</sup>. Thus, it has specific challenges in both diagnostic and management aspects<sup>9</sup>. In most cases, the detection of EPTB is often hard due to unclear clinical signs and the need for revascularization<sup>10</sup>. The EPTB appears with diverse signs in various situations; for this reason, it is known as "thousand faces infection<sup>11</sup>. Also, owing to EPTB having a different manifestation which may mimic other diseases it will make it more diagnostically challenging for laboratories, epidemiologists, and physicians<sup>12</sup>. Therefore, diagnostic delay confers its higher capability for creating disease, predominantly tuberculous meningitis (TBM), for that, EPTB merits further focus<sup>13, 14</sup>.

Iran is a country with an intermediate TB burden, with the report of 10290 new TB cases in 2015, of which 2863 (28.26%) were EPTB and 299 (2.95%) relapse cases<sup>15</sup>. The TB control strategy aims to reach <1 case per 1 million yearly by 2050 and an 80% decrease in TB incidence until 2030, in comparison with 2015<sup>16,</sup> <sup>17</sup>. But, similar to many other countries, TB remained a major cause of disease in Iran<sup>18</sup>.

Several risk factors are defined for the dissemination of EPTB, including patients who were age  $\geq$ 45 years, female, HIV+, excessive alcohol use, abnormal chest radiographs end-stage renal disease (ESRD), and diabetes<sup>19, 20</sup>.

Reviewing the trend of TB incidence during the time affords important measures to evaluate the outcome of controlling and managing programs and health policies for governments, and implanting the best control strategies<sup>21</sup>.

Treatment failure is the presence of persistent or repeatedly positive cultures during the treatment of tuberculosis. Usually, after 3 months of multi-drug therapy for pulmonary tuberculosis produced by the drug-susceptible bacterium, 90-95% of patients will have negative cultures and indicate clinical enhancement. Patients whose sputum cultures stay positive after 4 months of anti-tuberculosis therapy should be categorized as treatment failures<sup>18</sup>. The reasons for treatment failure in patients receiving appropriate anti-tuberculosis regimens are Nonadherence, drug resistance, malabsorption of drugs, and laboratory error. If treatment failure happens the patient should be referred to a local center. M. tuberculosis strains should be sent to a referral laboratory for drugsusceptibility testing against both first, and second-line drugs<sup>2</sup>. Therefore, this present study aimed to investigate the epidemiology, and trend of extrapulmonary tuberculosis, and the failure of treatment from 2004-2017 in Kashan, Iran.

# **Methods**

Study population and data extraction: A nonexperimental, retrospective cross-sectional study was conducted from 2004-2017 with newly registered extrapulmonary tuberculosis patients referred to the Referral Center for Tuberculosis in Kashan city, Isfahan province, Iran. In general, information on 159 extrapulmonary TB patients was extracted from Medical case records. The Medical records were filled and completed by the trained personnel in this center. In this study, a newly diagnosed extrapulmonary tuberculosis case was described as a diagnosis based on; one culturepositive, histological, or strong clinical evidence accordant with the extrapulmonary disease. TB-specific deaths included TB patients in whom TB was cited as the cause of death. Independent variables such as occupation, education, gender, nationality, history, age, and other related factors were studied and their correlation with EPTB was investigated. This should be noted that all patients declared that they didn't use narcotic drugs and alcohol. Lastly, the trend of extrapulmonary tuberculosis between 2004-2017 was depicted for EPTB patients of Kashan, Iran.

**Identification procedures:** In the diagnosis of Tuberculosis, direct smear microscopy alongside culture sputum specimens was used. Clinical specimens were homogenized with equal volumes of 50 mM NaOH comprising 0.5% N-acetyl-l-cysteine (NALC) and decontaminated with 10% sodium hydroxide, and then incubated at 37 °C. Consequently, Ziehl- Neelson

staining was used for TB diagnosis (21). Furthermore, clinical manifestations and radiographic parameters were assessed in all patients suspected to have tuberculosis.

**Ethical considerations:** This study was approved by the ethics committee of the Kashan University of Medical Science; IR.KAUMS.REC.1399.052.

**Statistical analysis:** Data were analyzed using SPSS software (version 19) by Kolmogorov-Smirnov, Chi-square, and Fisher's exact tests. *P values* of less than 0.05 were regarded as statistically significant.

#### Results

In total, 527 cases of Tuberculosis were reported, of which, 159 (30.17%) were confirmed extrapulmonary TB-positive cases. Eighty-five (53.5%) and 74 (46.5%) were male and female, respectively. Also, 74 (46.5%), and 84 (53.5%) of EPTB were from Iran, and Afghanistan immigrants, respectively. The average age of patients was 41.9±2.18. Among underlying diseases in extrapulmonary TB-positive, diabetes mellitus (DM) was predominant with a prevalence of 31 (19.5%), while, 128 (80.5%) cases did not show any underlying disease. Most of the patients were in the age group (21-40 years) with a frequency of 60 (37.7%), and the lowest of patients belonged to the age group (>80 years) with a frequency of 9 (5.7%). According to the occupational status, most of the patients were housewives with a frequency of 66 (41.5%), followed by workers at 36 (22%). Most of the patients were illiterate with a prevalence of 129




Figure 1. Annual trend of extrapulmonary tuberculosis cases since 2004-2017 in Kashan, Iran.

(81.1%), and only 9 (5.7%) patients had an academic education. In total, only 41 (25.8%) of patients had previous contact history with TB-positive patients. No correlation was found between the related factors listed in Table 1 and infection with EPTB (P> 0.05) (Table 1).

No cases of concurrent EPTB with PT have been documented. The cases of EPTB smear positive since 2004-2010 were not recorded in medicinal records, but since 2011-2017, 67 out of 73 cases (92%) were smeared positive. In total, 41 patients had the culture positive.

As shown in Table 2, 137 (86.2%) patients completed the treatment period, and 22 (13.8%) were absent from the treatment process. Of 159 patients, 150 (94.3%) were new cases, 4 (2.5%) were patients that had a previous TB relapse, and 5(3.1%) cases were imported from other cities in Iran or other foreign countries. Also, 155 (97.5%) were treated with first-line anti-TB drugs and 4 (2.5%) with second-line anti-TB drugs. Moreover, of total extrapulmonary TB, 69 (43.4%) were outpatient (Patients were referred to the TB center by physicians, health centers, or patients themselves referred to the health centers), and 90 (56.6%) of patients were hospitalized. Among types of extrapulmonary TB, most cases belonged to lymph nodes (19.5%), followed by each of the pleura, and bone, with a prevalence rate of 18.9%. But, the lowest was related to genital type with frequency 2(1.3%).

Annual case rates of EPTB have been recorded in Kashan since 2004. A relative drop in the rate of incidence was reported in the initial period of 2005. Then, a slight increase was evident from 2005-2007. A gradual increase was observed from 2007 until 2011, followed by a sharp increase in 2012, and also, a sharp decrease in 2013. From 2014-2017, there was a variation as a slight increase/decrease trend. In total, a consistent level of EPTB cases in Kashan about 30% of the total reported TB cases yearly explains the incidence rate of EPTB reported during 2004-2017. But, from the initial (2004) until the recent (2017), a relative decrease was observed (Figure 1). Also, we did not find any relationship between associated factors and failure of treatment (P>0.05).

internationally decreased by 37% in the community<sup>22</sup>.

**Table 1:** Demographic characteristic of registered extrapulmonary tuberculosis patients referred to the Kashan Referral

 Center for Tuberculosis.

Characteristics		Number(N)	Percent (%)	P value
Gender	Male	85	53.5	0.2
	Female	78	46.5	
Nationality	Iran	74	46.5	0.06
-	Afghanistan	85	53.5	
	0-20	28	17.6	
Age groups	21-40	60	37.7	0.2
	41-60	38	23.9	
	61-80	24	15.1	
	>80	9	5.7	
	Illiterate	129	81.1	0.2
Education	Diploma	21	13.2	
	>Diploma	9	5.7	
Underlying diseases	Yes	31	19.5	0.2
	No	128	80.5	
History contact with TB	Yes	41	25.8	0.1
-	No	118	74.2	
	Student	9	5.7	
	House- wives	66	41.5	
	Worker	35	22	0.1
Occupation	Employee	2	1.3	
	Farmer	8	5	
	Retired	13	8.2	
	Unemployed	8	5	
	Free	10	6.3	
	Other	8	5	

**Table 2:** Variables and factors related to registered extrapulmonary tuberculosis patients referred to the Kashan Referral

 Center for Tuberculosis.

Variables		Number(N)	Percent (%)	
Status	Outpatient	69	43.4	
	Hospitalized	90	56.6	
	Pleura	30	18.9	
	Lymph-node	31	19.5	
	Bone	30	18.9	
	Gastro	17	10.7	
Type of extra TB	Skin	5	3.1	
	Genital	2	1.3	
	Urinary	6	3.8	
	CNS	4	2.5	
	Other	34	21.4	
	New	150	94.3	
Case disease	Import	5	3.1	
	Relapse	4	2.5	
Therapeutic regimen	Anti-TB first-line drugs	155	97.5	
	Anti-TB second-line drugs	4	2.5	
Results of treatment	Complete treatment	137	86.2	
	Absent of treatment	22	13.8	

# Discussion

Tuberculosis (TB) still has remained a major health concern worldwide<sup>3</sup>. In recent decades active TB rate especially pulmonary tuberculosis (PTB) has Nevertheless, the frequency of extrapulmonary tuberculosis (EPTB) has stayed constant almost worldwide<sup>23</sup>. Extra-pulmonary TB indicates tuberculosis infection which has spread from the lung hematogenous or through the lymphatic system<sup>24</sup>. In

contrast to pulmonary tuberculosis (PTB), studies about EPTB are significantly smaller and have received less attention from authorities, particularly, in developing countries, probably because extrapulmonary TB is less transmissible than pulmonary,<sup>25</sup> or difficulties in diagnosis<sup>26</sup>.

The incidence rate of EPTB in this study was 159 (30.17%), the results obtained are comparable with data reported by Iranian Center for Diseases Control and Prevention (CDC) in 2011 reported the prevalence of pulmonary as 14.6 per 100000 people, of which 4.12 had extrapulmonary TB<sup>27</sup>. In neighboring countries of us, such as Oman<sup>28</sup>, India<sup>29</sup>, and Saudi Arabia<sup>30</sup>, EPTB accounted for respectively 37%, 16%, and 57.5% of all reported TB cases. Other studies from Iran showed such a pattern previously. Similarly, Rafiee et al. in northeast Iran<sup>18</sup>, Ghaffari-Fam et al. in North Iran (Babol)<sup>31</sup>, and Yahyavi et al. in Southwest Iran(Baghmalek)<sup>27</sup> reported prevalence rates of 23%, 25%, and 12.5%, respectively.

The annual trend case of EPTB in Kashan from 2004 showed a relative drop in the rate of incidence in the initial period to 2005. Then, a slight increase was evident from 2005-2007. As well, a gradual increase was observed from 2007 until 2011, followed by a sharp increase in 2012, and also, a sharp decrease in 2013. From 2014-2017, there was a variation as a slight increase/decrease trend. In total, a consistent level of EPTB cases in Kashan about 30% of the total reported TB cases annually explains the prevalence rate of EPTB reported during 2004-2017. But, from the initial (2004) until the recent (2017), a relative decrease was recorded.

For our acknowledge, the Center for Disease Control and Prevention (CDC), reported that the ratio of EPTB among all TB cases remained high, and the decrease in TB from 1953 has almost belonged to pulmonary TB reduction and not to EPTB<sup>32</sup>. This variation and difference in extra-pulmonary TB between the present study and mentioned studies possibly referred to the variation in diagnostic methods; highly heterogeneous manifestation of EPTB, the lower yield of laboratory diagnostic tests for detection of EPTB from extrapulmonary samples, use of molecular and conventional methods in different locations, cytological studies, and/or pericardoscopy in recent years<sup>27</sup>. Based on our findings, lymph nodes followed by the pleura and bone were the main sites for EPTB aligned with many other studies reporting the same<sup>28, 33-35</sup>. Also, in the USA, a nationwide report shows lymphatic TB (40.4%) as the most frequent followed by pleural TB (19.8%), bone and joints TB (11.3%)<sup>23</sup>, while, in the European Union (EU), the trend was different as it showed a higher predominance of pleural TB (36.7%), followed by lymphatic TB (30.5%)<sup>34</sup>.

In the present study, multivariable analyses were not found a correlation between factors included in the study (gender, age, occupation, history, nationality, education, and underlying disease) and infection with EPTB. Our findings are in contrast to other studies that revealed a relationship between the female sex<sup>23, 36</sup>, and age<sup>37</sup> as risk factors for EPTB. In general, extrapulmonary TB affects individuals in young children (<15 years of age) and older adults (>65 years of age)<sup>38, 39</sup>. But contrary to these reports, our study showed that most of the patients were in the age group (21-40), followed by the age group (41-60). But in fact, no correlation was found between the age factor and EPTB.

In the current study, among underlying diseases in extrapulmonary TB-positive, diabetes mellitus (DM) was predominant, but we did not find any relationship between DM and EPTB. In agreement with our study, a study from China<sup>38</sup>, Taiwan<sup>40</sup>, and Brazil<sup>25</sup> reported the same, and also they did not report a significant association. But contrasting findings from a study conducted in the United States showed the correlation between diabetes and increasing extrapulmonary TB risk<sup>41</sup>.

Tuberculosis is more common among men than women particularly in adults with difficult occupations<sup>42</sup>, accordingly, among Iranian people; tuberculosis prevalence is also higher among males than females<sup>43</sup>. Our study showed a higher prevalence of EPTB in males than females. This subject might be explainable by the presence of men in the community, and more exposure to the carriers and risk factors of EPTB<sup>43</sup>, although, the present study did not show a significant relationship between independent factors (sex, and occupation) and EPTB. The epidemiological profile in the current study reflects the nationality of patients, with a predominance of Afghanistan immigrant patients than Iranian, as more than half of EPTB cases belonged to Afghan refugees. According to the report of the UN Refugee Agency, by end of 2005, Iran had been the host of the third largest refugee population in all over the world, with a total of 716,000 refugees<sup>43</sup>. The prevalence of tuberculosis in the population of immigrants is very high and often reflects the undesirable situation of the disease in Afghanistan<sup>44</sup>. Immigrants mostly encounter many obstacles to accessing diagnostic and medicinal settings<sup>45</sup>, and they certainly have a significant impact on the epidemiology of tuberculosis in Iran<sup>46</sup>.

Most of the patients in our study were illiterate, although was not found a significant relationship between education and the EPTB, However, this causes a longer diagnostic delay among illiterate patients<sup>47</sup>. Also, most of the patients were housewives, or laborers, while, no correlation was found between occupation and EPTB. Nevertheless, patients living at low economic levels, and in poverty, exposing to an increased risk of poor health outcomes, unsuitable use of medications, and delay in referring to physicians, and treatment<sup>48, 49</sup>.

The outcome of treatment in the present study showed that almost all patients were exposed and treated with anti-TB first-line drugs. Almost patients completed the treatment and there was no treatment failure, and also, no case of death was observed. Contrary to our findings, others reported failure between 7-34%<sup>50, 51</sup>. The important reasons for this failure were; irregular treatment followed by alcohol abuse, illiteracy, and smoking<sup>52, 53</sup>. Also, Tekle et al. have declared the reasons for the failure of treatment as being a lack of family support, inadequate knowledge of treatment duration, and side effects of drugs<sup>50</sup>.

Adama Diallo and et. al showed that the delay between initiation of treatment and first sputum-smear investigation, also weight loss between diagnosis and first sputum-smear investigation were factors related to treatment failure of first-line pulmonary tuberculosis.

Moreover, high bacterial load at the first sputumsmear investigation was similarly related to first-line pulmonary tuberculosis treatment failure. Furthermore, they showed that the patient's weight loss between the diagnosis and the first bacilloscopic examination augmented the odds of treatment failure<sup>54</sup>. Among patients, the most common reason for the failure of TB drugs includes; traveling journeys, the finish of health facilities during strikes, and the absence of healthcare personnel to afford TB drugs<sup>55</sup>. Finally, the high rate of EPTB in Kashan and all over Iran might be due to poor case detection of EPTB; and illegal and legal immigrants from neighboring countries with a high burden of TB, this requires further assessment by examining case detection strategies in the country. Also, positive patients would be subjected to anti-tuberculosis drugs before being allowed entrance into our country.

#### Conclusion

Our findings showed that the prevalence of EPTB was significant in Kashan, but, a relative decrease was observed from 2004-2017. Also, a high rate of EPTB associated with Afghan patients was recorded in Kashan. This requires that illegal and legal immigration of people affected by tuberculosis be considered from other countries with a high burden of disease, and positive patients would be subjected to antituberculosis drugs before being allowed entrance into our country.

# Acknowledgment

None.

# Funding

This study was financially supported by Vice-Chancellor of Research, Kashan University of Medical Sciences, Kashan, Iran [Grant number: 99071].

#### References

1. Amiri MJ, Karami P, Chichaklu AH, Jangan EH, Amiri MJ, Owrang M, et al. Identification and Isolation of Mycobacterium tuberculosis from Iranian Patients with Recurrent TB using Different Staining Methods. J Res Med Dent Sci. 2018;6(2):409-14.

2. Ashna H, Kaffash A, Khaledi A, Ghazvini K. Mutations of rpob Gene Associated with Rifampin Resistance among Mycobacterium Tuberculosis Isolated in Tuberculosis Regional Reference Laboratory in Northeast of Iran during 2015-2016. Ethiopian Journal of Health Sciences. 2018;28(3):299-304.

3. Amiri MRJ, Siami R, Khaledi A. Tuberculosis Status and Coinfection of Pulmonary Fungal Infections in Patients Referred to Reference Laboratory of Health Centers Ghaemshahr City during 2007–2017. Ethiopian journal of health sciences. 2018;28(6):683.

4. Organization WH. Global tuberculosis report 2018. Geneva: World

Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. WHO/CDS/TB/2018.20. Available from: http://apps. who. int/iris/bitstream ...; 2019.

5. Nasehi M, Mirhaghaani L. Guideline for National Tuberculosis Control. Tehran: Ministry of Health and Medical Education. 2014.

6. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, Akksilp S, et al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. International Journal of Infectious Diseases. 2009;13(6):722-9.

7. Aaron L, Saadoun D, Calatroni I, Launay O, Memain N, Vincent V, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clinical microbiology and infection. 2004;10(5):388-98.

8. Pollett S, Banner P, O'Sullivan MV, Ralph AP. Epidemiology, diagnosis and management of extra-pulmonary tuberculosis in a low-prevalence country: a four year retrospective study in an Australian Tertiary Infectious Diseases Unit. PloS one. 2016;11(3):e0149372.

9. Barry C, Waring J, Stapledon R, Konstantinos A. Tuberculosis notifications in Australia, 2008 and 2009. Communicable diseases intelligence quarterly report. 2012;36(1):82.

10. Roberts-Witteveen AR, Christensen A, McAnulty JM. EpiReview: tuberculosis in NSW, 2008. New South Wales public health bulletin. 2010;21(8):174-82.

11. Hussein MM, Mooij JM, Roujouleh H, editors. Tuberculosis and chronic renal disease. Seminars in dialysis; 2003: Wiley Online Library.

12. Yoon HJ, Song YG, Kim JM, Chang KH, Choi JP, Park WI. Clinical manifestations and diagnosis of extrapulmonary tuberculosis. 2004.

13. Tay E. Innovative use of tuberculosis surveillance data to inform practice & policy. Advances in Tuberculosis: Australian and Regional Perspectives. 2013:14-5.

14. Porkert MT, Sotir M, Parrott-Moore P, Blumberg HM. Tuberculous meningitis at a large inner-city medical center. The American journal of the medical sciences. 1997;313(6):325-31.

15. Arsang-Jang S, Mansourian M, Amani F, Jafari-Koshki T. Epidemiologic trend of smear-positive, smear-negative, extra pulmonary and relapse of tuberculosis in iran (2001-2015); a repeated cross-sectional study. Journal of research in health sciences. 2017;17(2).

16. Siroka A, Ponce NA, Lönnroth K. Association between spending on social protection and tuberculosis burden: a global analysis. The Lancet Infectious Diseases. 2016;16(4):473-9.

17. Zumla A, George A, Sharma V, Herbert RHN, Oxley A, Oliver M. The WHO 2014 global tuberculosis report—further to go. The Lancet Global Health. 2015;3(1):e10-e2.

18. Rafiee S, Besharat S, Jabbari A, Golalipour F, Nasermoaadeli A. Epidemiology of tuberculosis in northeast of Iran: a population-based study. Iranian Journal of Medical Sciences. 2009;34(3):193-7.

19. Qian X, Nguyen DT, Lyu J, Albers AE, Bi X, Graviss EA. Risk factors for extrapulmonary dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis. Emerging microbes & infections. 2018;7(1):1-14.

20. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. Clinical infectious diseases. 2004;38(2):199-205.

21. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis.

Statistics in medicine. 2009;28(29):3670-82.

22. Organization WH. Global tuberculosis report 2013: World Health Organization; 2013.

23. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clinical Infectious Diseases. 2009;49(9):1350-7.

24. Standards D, Adults CoTi, Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376-95.

25. Gomes T, Reis-Santos B, Bertolde A, Johnson JL, Riley LW, Maciel EL. Epidemiology of extrapulmonary tuberculosis in Brazil: a hierarchical model. BMC infectious diseases. 2014;14(1):9.

26. Sanches I, Carvalho A, Duarte R. Who are the patients with extrapulmonary tuberculosis? Revista Portuguesa de Pneumologia (English Edition). 2015;21(2):90-3.

27. Yahyavi M, Delavari A, Karimi Z, Falsafi-Zadeh S, Samieifar S, Abbasi F, et al. Epidemiological Survey of Extrapulmonary Tuberculosis in Baghmalek City of Khuzestan Province in Iran (2007-2011). Jundishapur Journal of Chronic Disease Care. 2015;4(2).

28. Gaifer Z. Epidemiology of extrapulmonary and disseminated tuberculosis in a tertiary care center in Oman. International journal of mycobacteriology. 2017;6(2):162.

29. Organization WH. Tuberculosis control in the South-East Asia region: annual TB report 2014. 2014.

30. Al-Otaibi F, El Hazmi MM. Extra-pulmonary tuberculosis in Saudi Arabia. Indian Journal of Pathology and Microbiology. 2010;53(2):227.

31. Ghaffari-Fam S, Hosseini SR, Heydari H, Vaseghi-Amiri R, Daemi A, Nikbakht HA. Epidemiological patterns of Tuberculosis disease in the Babol, Iran. Analyt Res Clin Med. 2015;3(3):146-9.

32. Adada H, Valley M, Nour S, Mehta J, Byrd R, Anderson J, et al. Epidemiology of extra-pulmonary tuberculosis in the United States: high rates persist in the post-HIV era. The International Journal of Tuberculosis and Lung Disease. 2014;18(12):1516-21.

33. Kruijshaar ME, Abubakar I. Increase in extrapulmonary tuberculosis in England and Wales 1999–2006. Thorax. 2009;64(12):1090-5.

34. Sandgren A, Hollo V, Van der Werf M. Extrapulmonary tuberculosis in the European Union and European economic area, 2002 to 2011. Eurosurveillance. 2013;18(12):20431.

35. Mohammadien H, Alkhayat K, Hamed A, Shaaban M. Patterns, trends and treatment outcomes of extra-pulmonary tuberculosis in Sohag, Upper Egypt. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(2):313-6.

36. García-Rodríguez JF, Álvarez-Díaz H, Lorenzo-García MV, Mariño-Callejo A, Fernández-Rial Á, Sesma-Sánchez P. Extrapulmonary tuberculosis: epidemiology and risk factors. Enfermedades infecciosas y microbiologia clinica. 2011;29(7):502-9.

37. Lin C-Y, Chen T-C, Lu P-L, Lai C-C, Yang Y-H, Lin W-R, et al. Effects of gender and age on development of concurrent extrapulmonary tuberculosis in patients with pulmonary tuberculosis: a population based study. PLoS One. 2013;8(5):e63936.

38. Pang Y, An J, Shu W, Huo F, Chu N, Gao M, et al. Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008–2017.

Emerging infectious diseases. 2019;25(3):457.

39. Dayalan MR, Johnson HD, Kasinathan G, Pillai N. Unusual Presentations of Tuberculosis: A Case Series. Open Access Library Journal. 2016;3(03):1.

40. Lin J, Lai C, Chen Y, Lee S, Tsai S, Huang C, et al. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2009;13(5):620-5.

41. Magee M, Foote M, Ray S, Gandhi N, Kempker R. Diabetes mellitus and extrapulmonary tuberculosis: site distribution and risk of mortality. Epidemiology & Infection. 2016;144(10):2209-16.

42. Babamahmoodi F, Alikhani A, Yazdani Charati J, Ghovvati A, Ahangarkani F, Delavarian L, et al. Clinical epidemiology and paraclinical findings in tuberculosis patients in north of Iran. BioMed research international. 2015;2015.

43. Bialvaei AZ, Asgharzadeh M, Aghazadeh M, Nourazarian M, Kafil HS. Challenges of Tuberculosis in Iran. Jundishapur Journal of Microbiology. 2017;10(3).

44. Mayor S. Report on health of migrants to UK shows high risk of TB and HIV. British Medical Journal Publishing Group; 2006.

45. Minetti A, Camelique O, Hsa Thaw K, Thi S, Swaddiwudhipong W, Hewison C, et al. Tuberculosis treatment in a refugee and migrant population: 20 years of experience on the Thai-Burmese border. The International Journal of Tuberculosis and Lung Disease. 2010;14(12):1589-95.

46. Gai RT, Xu L, Song P, Huang Y. The rural-to-urban migrant population in China: gloomy prospects for tuberculosis control. Bioscience trends. 2011;5(6):226-30.

47. Okita K. Gender and literacy: factors related to diagnostic delay and unsuccessful treatment of tuberculosis in the mountainous area of Yemen. The International Journal of Tuberculosis and Lung Disease. 2005;9(6):680-5.

48. Marais B, Hesseling A, Cotton M. Poverty and tuberculosis: is it truly a simple inverse linear correlation? European Respiratory Journal. 2009;33(4):943-4.

49. Prevention OoD, Health HPUDo, Services H. National action plan to improve health literacy: US Department of Health & Human Services; 2010.

50. Tekle B, Mariam D, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. The International Journal of Tuberculosis and Lung Disease. 2002;6(7):573-9.

51. Chandir S, Hussain H, Salahuddin N, Amir M, Ali F, Lotia I, et al. Extrapulmonary tuberculosis: a retrospective review of 194 cases at a tertiary care hospital in Karachi, Pakistan. JPMA The Journal of the Pakistan Medical Association. 2010;60(2):105.

52. Ravikumar P, Priyadarshini Bai G. A study of extra-pulmonary tuberculosis and its outcome. International Journal of Advances in Medicine. 2017;4(1):209.

53. Chandrasekaran V, Gopi P, Subramani R, Thomas A, Jaggarajamma K, Narayanan P. Default during the intensive phase of treatment under DOTS programme. Indian Journal of Tuberculosis. 2005;52(4):197-202.

54. Diallo A, Dahourou DL, Tassembedo S, Sawadogo R, Meda N. Factors associated with tuberculosis treatment failure in the Central East Health region of Burkina Faso. The Pan African Medical Journal. 2018;30.

55. Sawadogo B, Tint KS, Tshimanga M, Kuonza L, Ouedraogo L. Risk factors for tuberculosis treatment failure among pulmonary tuberculosis patients in four health regions of Burkina Faso, 2009: case control study. Pan African medical journal. 2015;21(1).